Medical/Pharmaceuticals
One Journey, Two Experiences: Heal And Explore In Selangor
JAKARTA, Indonesia, Oct. 15, 2026 /PRNewswire/ -- Selangor continues to strengthen its position as a preferred medical tourism destination in Southeast Asia, particularly among Indonesian travellers, through its combination of internationally accredited healthcare facilities, excellent accessibil...
2026-10-15 17:06
3567
HMI Medical Unveils New Brand Identities Across Its Healthcare Facilities in Malaysia As Regional Cross-border Healthcare Grows
The refreshed identities of HMI Medical's hospitals and medical centre in Malaysia signal the Group's commitment to deliver more with care by sparking change for the future of healthcare SINGAPORE and KUALA LUMPUR, Malaysia, Oct. 15, 2026 /PRNewswire/ -- HMI Medical is strengthening its regional...
2026-10-15 12:25
3554
NTL HEALTHCARE Launches On-Premises AI Solution 'CerviCARE® AI AT' Globally
Supports Local AI Analysis and Data Management, Retains Core CerviCARE® AI Features, and Adds DICOM File Generation SEONGNAM, South Korea, Oct. 15, 2026 /PRNewswire/ -- NTL HEALTHCARE, a women's health AI company, announced the global launch of CerviCARE® AI AT, an on-premises version of its AI-...
2026-10-15 10:00
2269
Opella: New study demonstrates successful cough treatment extends beyond symptom relief
PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic ...
2026-10-15 07:01
1958
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity ...
2026-10-14 20:00
1933
NueCell Bio Joins CIRM's Industry Resource Partner Program to Support California's Stem Cell and Gene Therapy Innovators
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced today it has joined the Industry Resource Partnership (IRP) Program of the California Institute for Regenerative Medici...
2026-10-14 15:00
2106
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in ...
2026-10-14 13:00
2877
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a pa...
2026-10-14 10:25
2428
Osara Health and Medibank partner to bring one-on-one cancer coaching to members
From 14 October, eligible Medibank members living with cancer can access Osara Health's Cancer Coach program for personalised support with the physical and emotional challenges of diagnosis and treatment. SYDNEY, Oct. 14, 2026 /PRNewswire/ -- Osara Health has partnered with Medibank, one of Aust...
2026-10-14 05:11
2726
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping th...
2026-10-14 04:20
2737
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...
2026-10-13 20:00
2888
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...
2026-10-13 19:23
2662
The Right Doctor Isn't Always One Doctor
Why complex brain and spine conditions increasingly call for specialists to work across disciplines. KUALA LUMPUR, Malaysia, Oct. 13, 2026 /PRNewswire/ -- When faced with a brain, spine or neurological condition, one of the first questions a patient or family member may ask is: Which doctor sh...
2026-10-13 16:15
1681
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...
2026-10-13 15:00
6569
World Thrombosis Day campaign urges global action to protect women against blood clots
Global campaign brings together partners to raise awareness of women's unique blood clot risks, recognize warning signs and take action to prevent life-threatening events. CHARLOTTE, N.C., Oct. 13, 2026 /PRNewswire/ -- One in four people worldwide die from conditions caused by thrombosis, yet bl...
2026-10-13 14:00
2205
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company...
2026-10-13 09:00
3181
GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that i...
2026-10-13 08:15
3442
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting sten...
2026-10-13 02:11
3301
Fair2Care: Canton Fair Launches International Medical Experience for the First Time
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- The 140th Canton Fair will open on October 15 with a brand-new experience for attendees. For the first time, the Fair is introducing an exclusive Fair2Care International Medical Experience Program. The program features a dual experience model that c...
2026-10-12 21:01
2969
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for ...
2026-10-12 18:50
2049
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 307 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
36572
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
35733
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
34483
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
28871
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
17778
